ACOR News and Press, Acorda Therapeutics Inc. From 07/28/20

Acorda Therapeutics, Inc. (NASDAQ: ACOR) will host a conference call and webcast in conjunction with its second quarter 2020 update and financial results on Tuesday, August 4 at 4:30 p.m. ET. To participate in the Webcast/Conference call, please note there is a new pre-registration proces...

The following slide deck was published by Acorda Therapeutics, Inc. in conjunction with their 2020 Q1 earnings Read more ...

NEW YORK , May 6, 2020 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P 100, S&P MidCap 400, and S&P SmallCap 600 effective prior to the opening on Tuesday, May 12 : DexCom Inc. (NASD:DXCM) will replace Allergan plc (NY...

DexCom (NASDAQ: DXCM ) is up 4.3% postmarket as it's making a move to the S&P 500 , to replace Allergan (NYSE: AGN ) - set to be acquired by AbbVie. More news on: DexCom, Inc., Allergan plc, salesforce.com, inc., Consumer stocks news, Financial stocks news, Tech stocks news, Stocks ...

Acorda Therapeutics, Inc. (ACOR) Q1 2020 Earnings Conference Call May 05, 2020, 16:30 ET Company Participants Tierney Saccavino - EVP, Corporate Communications Ron Cohen - Founder, CEO, President & Director Conference Call Participants Michael Yee - Jefferies Alexander ...

Acorda Therapeutics (NASDAQ: ACOR ): Q1 Non-GAAP EPS of -$0.51 misses by $0.10 ; GAAP EPS of -$0.14 beats by $0.31 . More news on: Acorda Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

INBRIJA ® (levodopa inhalation powder) 1Q 2020 net revenue of $4.4 million AMPYRA ® (dalfampridine) 1Q 2020 net revenue of $20.1 million Reiterates 2020 AMPYRA net revenue guidance and operating expense guidance Withdraws 2020 INBRIJA net revenue guidance due to the...

Acorda Therapeutics, Inc. (NASDAQ: ACOR) will host a conference call and webcast in conjunction with its first quarter 2020 update and financial results on Tuesday, May 5 at 4:30 p.m. ET. To participate in the conference call, please dial (833) 236-2756 (domestic) or (647) 689-4181 (inter...

Acorda Therapeutics ( ACOR ) is in a better position after addressing the convertible note overhang last year. In my previous article , I noted the company is uninvestable due to this substantial financing overhang as the company lacked the cash to pay the noteholders in 2021 and the conversi...

Original Post Editor's Note : The summary bullets for this article were chosen by Seeking Read more ...